Hepcidin: A novel peptide hormone regulating iron metabolism

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 823-830

  Singh, Bhawna ^a   Arora, Sarika ^b   Agrawal, Poonam ^b   Gupta, S K ^c  

^a G B PANT HOSPITAL   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Anemia of cancer; Anemia of chronic disease; Hepcidin; Hereditary hemochromatosis; Iron metabolism; Rheumatoid arthritis

Indexed keywords

HEPCIDIN;

ANEMIA; ATHEROSCLEROSIS; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENTERITIS; HEMOCHROMATOSIS; HUMAN; INNATE IMMUNITY; IRON METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS; THALASSEMIA;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CLINICAL CHEMISTRY TESTS; HOMEOSTASIS; HORMONES; HUMANS; IMMUNITY, INNATE; IRON;

EID: 79954990652     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.02.014     Document Type: Review

References (108)

1. Aisen P., Enns C., Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001, 33:940-959.
2. Krause A., Nietz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480:147-150.
3. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810.
4. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276:7811-7819.
5. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110:1037-1044.
6. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001, 98:8780-8785.
7. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004, 11:251-254.
8. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
9. Hunter H.N., Fulton D.B., Ganz T., Vogel H.J. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 2002, 277:37597-37603.
10. Kemna E.H.J.M., Tjalsma H., Podust V.N., Swinkels D.W. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007, 53:620-628.
11. Hepcidin Ganz T. A regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005, 18:171-182.
12. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005, 106:2196-2199.
13. Nemeth E., Preza G.C., Jung C.L., Kaplan J., Waring A.J., Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006, 107:328-333.
14. Risso A. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukoc Biol 2000, 68:785-792.
15. Nicolas G., Bennoubn M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. PNAS 2002, 99:4596-4601.
16. Fleming M.D., Andrews N.C. Mammalian iron transport: an unexpected link between metal homeostasis and host defense. J Lab Clin Med 1998, 132:464-468.
17. Fleming M.D., Trenor C.C., Su M.A., et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997, 16:383-386.
18. Andrews N.C. Metal transporters and disease. Curr Opin Chem Biol 2002, 6:181-186.
19. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341:1986-1995.
20. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006, 507:29-35.
21. Fleming R.E., Sly W.S. Hepcidin: a putative iron regulatory hormone relative to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A 2001, 98:8160-8162.
22. Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 2002, 417:552-555.
23. Finch C. Regulators of iron balance in humans. Blood 1994, 84:1697-1702.
24. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
25. De Domenico I., Mc Vey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008, 9:72-81.
26. Njajou O.T., de Jong G., Berghuis B., et al. Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis 2002, 29:439-443.
27. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006, 107:3727-3732.
28. Merle U., Fein E., Gehrke S.G., Stremmel W., Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007, 148:2663-2668.
29. Bekri S., Gaul P., Anty R., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterologia 2006, 131:788-796.
30. Dallalio G., Law E., Means R.T. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006, 107:2702-2704.
31. Gangaidzo I.T., Moyo V.M., Mvundura E., et al. Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis 2001, 184:936-939.
32. Braun V., Killmann H. Bacterial solutions to the iron-supply problem. Trends Biochem Sci 1999, 24:104-109.
33. Jurado R.L. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997, 25:888-895.
34. Collins H.L. The role of iron in infections with intracellular bacteria. Immunol Lett 2003, 85:193-195.
35. Marx J.J. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002, 15:411-426.
36. Walker E.M., Walker S.M. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000, 30:354-365.
37. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Investig 2002, 32(Suppl. 1):70-78.
38. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001, 11:66-75.
39. Recalcati S., Pometta R., Levi S., Conte D., Cairo G. Response of monocyte iron regulatory protein activity to inflammation: abnormal behavior in genetic hemochromatosis. Blood 1998, 91:2565-2572.
40. Weiss G., Fuchs D., Hausen A., et al. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992, 20:605-610.
41. Weinberg E.D. Modulation of intramacrophage iron metabolism during microbial cell invasion. Microbes Infect 2000, 2:85-89.
42. Zwilling B.S., Kuhn D.E., Wikoff L., Brown D., Lafuse W. Role of iron in Nramp1-mediated inhibition of mycobacterial growth. Infect Immun 1999, 67:1386-1392.
43. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102(3):783-788.
44. Dey R., Datta S.C. Leishmanial glycosomes contain superoxide dismutase. Biochem J 1994, 301:317-319.
45. Zhang Y., Lathigra R., Garbe T., Catty D., Young D. Genetic analysis of superoxide dismutase, the 23kilodalton antigen of mycobacterium tuberculosis. Mol Microbiol 1991, 5:381-391.
46. Nicolas G., Viatte L., Bennoun M., Beaumont C., Kahn A., Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002, 29:327-335.
47. Kemna E.H.J.M., Tjalsma H., Willems H.L., Swenkels D.W. Hepcidin: from discovery to differential diagnosis. Haematologica 2008, 93:90-97.
48. Erslev A.J. Anemia of chronic disease. Williams hematology 2001, 481-486. McGraw-Hill, New York, NY. E. Beutler, B.S. Coller, M.A. Lichtman, T.J. Kipps, U. Seligsohn (Eds.).
49. Peyssonnaux C., Zinkernagel A.S., Schuepbach R.A., et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007, 117:1926-1932.
50. Silvestri L., Pagani A., Camaschella C. Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008, 111:924-931.
51. Shike H., Lauth X., Westerman M.E., et al. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem 2002, 269:2232-2237.
52. Tussing-Humphreys L.M., Nemeth E., Fantuzzi G., et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity 2010, 18:1449-1456.
53. Ganz T., Olbina G., Girelli D., Nemeth E., Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112:4292-4297.
54. Pak M., Lopez M.A., Gabayan V., Ganz T., Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006, 108:3730-3735.
55. Locke A., Main E.R., Rosbash D.O. The copper and non-hemoglobinous iron contents of the blood serum in disease. J Clin Invest 1932, 11:527-542.
56. Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101:4148-4154.
57. Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., Andrews N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002, 100:3776-3781.
58. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
59. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002, 16:87-96.
60. Means R.T. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003, 2:116-121.
61. Laftah A.H., Ramesh B., Simpson R.J., et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004, 103:3940-3944.
62. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36:77-82.
63. Konjin A., Hershko C. The anemia of inflammation and chronic disease. Iron in immunity, cancer and inflammation 1989, 111-143. Wiley and Sons, Chichester. M. Desousa, J.H. Brock (Eds.).
64. Cartwright G.E. The anemia of chronic disorders. Semin Hematol 1966, 3:351-368.
65. Means R.T., Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992, 80:1639-1647.
66. Kuiper-Kramer E.P., Huisman C.M., van Raan J., van Eijk H.G. Analytical and clinical implications of soluble transferrin receptor in serum. Eur J Clin Chem Clin Biochem 1996, 34:645-649.
67. Rivera S., Pastuszka M., Yu A., Ganz T. The role of hepcidin in anemia of inflammation and anemia of cancer. FASEB 2008, 22:1191.8.
68. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
69. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004, 113(9):1251-1253.
70. Cavill I. Iron and erythropoietin in renal disease. Nephrol Dial Transplant 2002, 17(Suppl. 5):19-23.
71. Sharma S., Nemeth E., Chen Y., et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008, 14:3262-3267.
72. Chung A.Y.F., Leo K.W., Wong G.C., Chuah K.L., Ren J.W., Lee C.G.L. Giant hepatocellular adenoma presenting with chronic iron deficiency anemia. Am J Gastroenterol 2006, 101:2160-2162.
73. Simon M., Bourel M., Genetet B., Fauchet R. Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977, 297:1017-1021.
74. Lyon E., Frank E.L. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 2001, 47:1147-1156.
75. De Domenico I., Ward D.M., Nemeth E., et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A 2005, 102:8955-8960.
76. Nicolas G., Viatte L., Lou D.Q., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34:97-101.
77. Bridle K.R., Frazer D.M., Wilkins S.J., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003, 361:669-673.
78. Swinkels D.W., Janssen M.C.H., Bergmans J., Marx J.J.M. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 2006, 52:950-968.
79. Adamsky K., Weizer O., Amariglio N., et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004, 124:123-124.
80. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 2005, 105:4103-4105.
81. Nemeth E., Roetto A., Garozzo G., Ganz T., Camaschella C. Hepcidin is decreased in TFR2-hemochromatosis. Blood 2005, 105:1803-1806.
82. Rivera S., Liu L., Nemeth E., Gabayan V., Sorensen O.E., Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005, 105:1797-1802.
83. Cunningham M.J., Macklin E.A., Neufeld E.J., Cohen A.R. Complications of beta-thalassemia major in North America. Blood 2004, 104:34-39.
84. Jayantha A., Sangwaiya A., Bhatkal B., Geoghegan F., Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol 2009, 21(4):425-429.
85. McGrath H., Rigby P.G. Hepcidin: inflammation's iron curtain. Rheumatology 2004, 43(11):1323-1325.
86. Sabine N., Klaus F., Jan W., Eduard F.S. Inflammatory bowel disease. Gut 2007, 56(9):1240-1247.
87. Bergamaschi G., Sabatino A., Albertini R., et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-treatment. Haematologica 2010, 95:199-205.
88. Kemna E.H.J.M., Kartikasari A.E.R., van Tits L.J.H., Pickkers P., Tjalsma H., Swinkels D.W. Regulation of hepcidin: insights from biochemical analysis on human serum samples. Blood Cells Mol Dis 2007, 40:339-346.
89. Roe M.A., Spinks C., Heath A.L., et al. Serum prohepcidin concentration: no association with iron absorption in healthy men, and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant woman. Br J Nutr 2007, 97:544-549.
90. Barany P., Divino Filho J.C., Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997, 29(4):565-568.
91. Cooper A.C., Mikhail A., Lethbridge M.W., Kemeny D.M., MacDougall I.C. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003, 14(7):1776-1784.
92. Eschbach J.W. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 2002, 13:1412-1414.
93. Swinkels D.W., Wetzels J.F.M. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 2008, 23(8):2450-2453.
94. Taes Y.E., Wuyts B., Boelaert J.R., De Vriese A.S., Delanghe J.R. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004, 42:387-389.
95. Malyszko J., Malyszko J.S., Pawlak K., Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am J Hematol 2006, 81:832-837.
96. Tomosugi N., Kawabata H., Wakatabe R., et al. Detection of serum hepcidin in renal failure and inflammation by using Protein Chip system. Blood 2006, 108(4):1381-1387.
97. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010, 49(1):15-24.
98. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet 1981, 1(8233):1293-1294.
99. Sullivan J.L. The iron paradigm of ischemic heart disease. Am Heart J 1989, 117:1177-1188.
100. Sullivan J.L. Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol 2005, 25:1532-1535.
101. Kraml P.J., Klein R.L., Huang Y., Nareika A., Lopes-Virella M.F. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism 2005, 54:453-459.
102. Minqin R., Rajendran R., Pan N., et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med 2005, 38:1206-1211.
103. Lee T.S., Shiao M.S., Pan C.C., Chau L.Y. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999, 99:1222-1229.
104. Kulaksiz H., Theilig F., Bachmann S., et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005, 184:361-370.
105. Kemna E., Tjalsma H., Laarakkers C., et al. Novel urine hepcidin assay by mass spectrometry. Blood 2005, 106:3268-3270.
106. Murphy A.T., Witcher D.R., Luan P., Wroblewski V.J. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007, 110:1048-1054.
107. Murao N., Ishigai M., Yasuno H., Shimonaka Y., Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007, 21:4033-4038.
108. Young B., Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009, 4:1384-1387.